Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial

被引：0
|
作者：
Yosuke Horita
Yasuhide Yamada
Ken Kato
Yoshinori Hirashima
Kouhei Akiyoshi
Kengo Nagashima
Takako Nakajima
Tetsuya Hamaguchi
Yasuhiro Shimada
机构：
[1] National Cancer Center Hospital,Gastrointestinal Oncology Division
[2] Toyama Prefectural Central Hospital,Department of Chemotherapy
[3] Oita University,Department of Medical Oncology, Faculty of Medicine
[4] Josai University,Laboratory of Biostatistics, Faculty of Pharmaceutical Sciences
来源：
International Journal of Clinical Oncology | 2012年 / 17卷
关键词：
FOLFIRI; Bevacizumab; Second-line; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：604 / 609
页数：5
相关论文
共 50 条
  • [1] Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial
    Horita, Yosuke
    Yamada, Yasuhide
    Kato, Ken
    Hirashima, Yoshinori
    Akiyoshi, Kouhei
    Nagashima, Kengo
    Nakajima, Takako
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2012, 17 (06) : 604 - 609
  • [2] A phase II clinical trial of metformin combined with FOLFIRI plus bevacizumab as second-line therapy in patients with RAS-mutant metastatic colorectal cancer
    He, Wen-zhuo
    Jiang, Chang
    Yi, Jiahong
    Xue, Ju
    Yin, Zhao-feng
    Dong, Wen-jing
    Xia, Liang-Ping
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
    Denda, Tadamichi
    Sakai, Daisuke
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Sunaga, Yoshinori
    Ziti-Ljajic, Samira
    Brillac, Claire
    Yoshino, Takayuki
    [J]. CANCER SCIENCE, 2019, 110 (03) : 1032 - 1043
  • [4] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Suzuki, Takeshi
    Shinozaki, Eiji
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Ichimura, Takashi
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
  • [5] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    [J]. SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [6] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Takeshi Suzuki
    Eiji Shinozaki
    Hiroki Osumi
    Izuma Nakayama
    Yumiko Ota
    Takashi Ichimura
    Mariko Ogura
    Takeru Wakatsuki
    Akira Ooki
    Daisuke Takahari
    Mitsukuni Suenaga
    Keisho Chin
    Kensei Yamaguchi
    [J]. Cancer Chemotherapy and Pharmacology, 2019, 84 : 307 - 313
  • [7] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    [J]. Surgery Today, 2011, 41 : 1067 - 1074
  • [8] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
    Li, Sheng
    Li, Xiaoyou
    Zhu, Qianni
    Gao, Jin
    Zhu, Chunrong
    Zhu, Liangjun
    [J]. CANCER CONTROL, 2024, 31
  • [9] A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
    Muro, Kei
    Kim, Tae Won
    Park, Young Suk
    Uetake, Hiroyuki
    Nishina, Tomohiro
    Nozawa, Hiroaki
    Matsumoto, Hiroshi
    Yamazaki, Kentaro
    Han, Sae-Won
    Lee, Keun-Wook
    Deng, Yanhong
    Buyse, Marc E.
    Satoh, Taroh
    Ryoo, Baek-Yeol
    Shen, Lin
    Iwasa, Satoru
    Morita, Satoshi
    Sakamoto, Junichi
    Xu, Rui-hua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study
    Tsutsumi, Soichi
    Ishibashi, Keiichiro
    Uchida, Nobuyuki
    Ojima, Hitoshi
    Hosouchi, Yasuo
    Yashuda, Naokuni
    Kigure, Wakako
    Yamauchi, Satoru
    Asao, Takayuki
    Ishida, Hideyuki
    Kuwano, Hiroyuki
    [J]. ONCOLOGY, 2012, 83 (03) : 151 - 157
12345